Other cannabinoids

Marijuana and Madness: Second Edition

Volumn , Issue , 2011, Pages 17-22

  Mechoulam, Raphael ^a   Hanus, Lumir ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84923533639     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511706080.003     Document Type: Chapter

References (49)

1. Adele, T., Stevenson, L. A., Wease, K. N., et al. (2005) Evidence that the plant cannabinoid Δ 9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Brit J Pharmacol, 146: 917-26.
2. Ahmed, S. A., Ross, S. A., Slade, D., Radwan, M. M., Khan, I. A., ElSohly, M. A. (2008a) Structure determination and absolute coni guration of cannabichromanone derivatives from high potency Cannabis sativa. Tetrahedron Lett, 49: 6050-3.
3. Ahmed, S. A., Ross, S. A., Slade, D., et al. (2008b) Cannabinoid ester constituents from high-potency Cannabis sativa. J Nat Prod, 71: 536-42. [Erratum] J. Nat. Prod, 71: 1119.
4. Ahrens, J., Demir, R., Leuwer, M., et al. (2009) The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function. Pharmacology 83: 217-22.
5. Appendino, G., Giana, A., Gibbons, S., et al. (2008) A polar cannabinoid from Cannabis sativa var. Carma. Nat Prod Commun, 3: 1977-80.
6. Avraham, Y., Israeli, E., Gabbay, E., et al. (2006) Cannabinoids affect neurological and cognitive function in thioacetamid-induced hepatic encephalopathy. Neurobiol Disease 21: 237-45.
7. Bradshaw, H. B., Rimmerman, N., Hu, S. S-J., et al. (2009) The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochemistry 10: 1-11.
8. Cascio, G. M., Gauson, L. A., Stevenson, L. A., Ross, R. A., Pertwee, R. G. (2009) Cannabigerol behaves as a potent alpha-2-adrenoreceptor partial agonist. 19th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, p. 73.
9. Chen, J., Wiley, J. L., Martin, B. R., Huffman, J. W. (2009) Synthesis of geminally dimethyl substituted analogues of Δ 8-THC. 19th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, p. 2.
10. Dagon, Y., Avraham, Y., Ilan, R., Mechoulam, R., Berry, E. M. (2007) Cannabinoids ameliorate cerebral function following liver failure via AMP-activated protein kinase. FASEB J. 21: 2431-41.
11. ElSohly, M. A., Slade, D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci, 78: 539-48.
12. Fezza, F., Bisogno, T., Minassi, A., Appendino, G., Mechoulam, R., Di Marzo, V. (2002) Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantii cation in rat tissues. FEBS Lett, 513: 294-8.
13. Gaoni, Y. and Mechoulam, R. (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc, 86: 1646-7.
14. Gauson, L. A., Cascio, G. M., Ross, R. A., Pertwee, R. G. (2009) Cannabigerol displays signii cant potency as a 5-HT 1A receptor antagonist. 19th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, p. 25.
15. Guy, G. and Pertwee, R. (2006) Cannabinoids, in particular tetrahydrocannabivarin, as CB receptor antagonists, and therapeutic use. PCT Int. Appl., WO 2006054057 A2 20060526.
16. Han, S., h atte, J., Jones, R. M. (2009) Recent advances in the discovery of CB2 selective agonists. Ann Rep Med Chem, 44: 227-46.
17. Hanuš, L. O. (2007) Discovery and isolation of anandamide and other endocannabinoids. Chem Biodiv, 4: 1828-41.
18. Hanuš, L. O. (2009a) Discovery and isolation of anandamide and other endocannabinoids. In Lambert, D. M. (ed) Cannabinoids in Nature and Medicine, Zurich: Verlag Helvetica Chimica Acta, Wiley VCH, pp. 251-66.
19. Hanuš, L. O. (2009b) Pharmacological and therapeutic secrets of plant and brain (Endo)Cannabinoids. Med Res Rev, 29: 213-71.
20. Hanuš L., Abu-Lai S., Fride E., et al. (2001) 2-Arachidonoyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci. USA, 98: 3662-5.
21. Huffman, J. W., Bushell, S. M., Joshi, S. N., Wiley, J. L., Martin, B. R. (2006) Enantioselective synthesis of 1-methoxyand 1-deoxy-2'-methyl-Δ 8-tetrahydrocannbinols: New selective ligands for the CB2 receptor. Bioorg Med Chem, 14: 247-62.
22. Krishnamurthy, M., Gurley, S., Moore, B. M. (2008) Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Δ 8-tetrahydrocannabinol analogs. Bioorg Med Chem, 16: 6489-500.
23. Ligresti, A., Moriello, A. S., Starowicz, K., et al. (2006) Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp ther, 318: 1375-87.
24. Liu, J., Wang, L., Harvey-White, J., et al. (2007) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacol, 54: 1-7.
25. Magen, I., Avraham, Y., Berry E., Mechoulam, R. (2008) Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Design, 14: 2362-9.
26. Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., Berry. E. M. (2009) Cannabidiol ameliorates cognitive and motor impairement in mice with bile duct ligatio n. J. Hepatology, 51: 528-34.
27. Mato, S., Vidal, R., Castro, E., Diaz, A., Pazos, A., Valdizan, E. M. (2009) Chronic l uoxetine modulates CB1 receptor mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-HT1A receptor dependent mechanism. Mol Pharmacol. (Epub ahead of print).
28. McAllister, S. D., Christian, R. T., Horowitz, M. P., Garcia, A., Desprez, P.-Y. (2007) Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer ther, 6: 2921-7.
29. Mechoulam, R. (2005) Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol, 146: 913-5.
30. Mechoulam, R. (2007b) Conversation with Raphael Mechoulam. Addiction, 102: 887-93.
31. Mechoulam, R., Shani, A., Edery, H., Grunfeld, Y. (1970) The chemical basis of hashish activity. Science, 169: 611-2.
32. Mechoulam, R., Peters, M., Murillo-Rodriguez, E., Hanuš, L. O. (2007a) Cannabidiol-Recent Advances. Chem Biodiv, 4: 1678-92.
33. Mechoulam, R., Peters, M., Murillo-Rodriguez, E., Hanuš, L. O. (2009) Cannabidiol-recent advances. pp. 83-101. In Lambert, D. M. (ed) Cannabinoids in Nature and Medicine, Zurich: Verlag Helvetica Chimica Acta, Wiley VCH, pp. 83-101.
34. Oka, S., Tsuchie, A., Tokumura, A., et al. (2003) Ether-linked analogue of 2-arachidonoyl glycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem, 85: 1374-81.
35. O'Sullivan, S. E. and Kendall, D. A. (2009) Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inl ammatory disease. Immunobiology (Epub ahead of print).
36. Pertwee, R. G. (2008a) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin. Brit J Pharmacol, 153: 199-215.
37. Pertwee, R. G. (2008b) Cannabigerol as CB1 and CB2 cannabinoid receptor agonist and therapeutic use. Patent Dec 31, GB 2450493 A.
38. Pertwee, R. G., Thomas, A., Stevenson, L. A., et al. (2007) The psychoactive plant cannabinoid, Δ 9-tetrahydrocannabinol, is antagonized by Δ 8-and Δ 9-tetrahydrocannabivarin in mice in vivo. Brit J Pharmacol, 150: 586-94.
39. Radwan, M. M., ElSohly, M. A., Slade, D., Ahmed, S. A., Khan, I. A., Ross, S. A. (2009) Biologically Active Cannabinoids from High-Potency Cannabis sativa. J Nat Prod, 72: 906-11.
40. Radwan, M. M., Ross, S. A., Slade, D., Ahmed, S. A., Zuli qar, F., ElSohly, M. A. (2008) Isolation and characterization of new cannabis constituents from a high potency variety. Planta Med, 74: 267-72.
41. Richardson, D., Ortori, C. A., Chapman, V., Kendall, D. A., Barrett, D. A. (2007) Quantitative proi ling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal Biochem, 360: 216-26.
42. Ross, S. A., ElSohly, M. A., Sultana, G. N. N., Mehmedic, Z., Hossain, C. F., Chandra, S. (2005) Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L. Phytochem Anal, 16: 45-8.
43. Ross, S. A., Radwan, M. M., Ahmed, S. A., et al. (2009) Binding ai nities of minor cannabis constituents to CB1 and CB2 receptors. 19th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, p. 74.
44. Scuderi, C., De Filippis, D., Iuvone, T., Blasio, A., Steardo, A., Esposito, G. (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res, 23: 597-602.
45. Snider, N. T., Nast, J. A., Tesmer, L. A., Hollenberg, P. F. (2009) A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid Receptor 2-selective agonist. Mol Pharmacol, 75: 965-72.
46. Snider, N. T., Sikora, M. J., Sridar, C., Feuerstein, T. J., Rae, J. M., Hollenberg, P. F. (2008) The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp ther, 327: 538-45.
47. Tan, B., O'Dell, D. K., Yu, Y. W., et al. (2010) Identii cation of endogenous acyl amino acids based on a targeted lipidomics approach. J Lipid Res, 51: 112-9.
48. Wilkinson, J. D. and Williamson, E. M. (2007) Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci, 45: 87-92.
49. Zanelati, T., Biojone, C., Moreira, F., Guimar a es, F., and Joca, S. (2009) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT receptors. Br J Pharmacol (Epub ahead of print).